Dr. Reddy's to Acquire a Portfolio of 42 Abbreviated New Drug Applications (ANDA) in the US
Shots:
- Dr. Reddy’s acquires a portfolio of 42 approved- non-marketed Abbreviated New Drug Applications (ANDAs) in the US- including >30 generics injectable
- The focus of the acquisition is to enhance Dr. Reddy’s injectable portfolio in the US and globally
- Dr. Reddy’s will launch the products within the next one to two years and according to IQVIA the products produced ~$645M revenue in 2018 in the US
Ref: Dr. Reddy's | Image: Twitter
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com
